Documenting Adverse Events As A Clinical Research Coordinator

The video introduces a presentation segment for the Site Owner Academy, focusing on the tactical topic of documenting adverse events (AEs) for clinical research coordinators. The presenters share their experience as site owners and former study coordinators, emphasizing the importance of understanding AEs from both sponsor and site perspectives.

A significant challenge is the identification of AEs. Coordinators often miss AEs reported by patients to investigators or documented in patient-reported outcomes (PROs). This can happen because patients don't repeat information, or coordinators are too busy to thoroughly review all notes. CRAs frequently discover these overlooked AEs during monitoring visits, which can lead to compliance issues.

An adverse event is any unexpected medical event related to a patient in a clinical trial, regardless of its causal relationship with the experimental treatment. It encompasses any experience that is not typically healthy for the patient and is not part of their pre-existing medical history. If a pre-existing condition worsens, it also qualifies as an AE.

Every site must have a method for documenting AEs, usually through a log, which ultimately feeds into the Electronic Data Capture (EDC) system. CRAs monitor the EDC data closely as it's what the FDA reviews. It's crucial not to assume an AE is unrelated or minor; any abnormal event must be reported. The coordinator's role is to capture the data, not to make medical judgments about causality.

AEs begin as soon as the informed consent is signed, not when the study drug is administered. If a pre-existing medical condition, like hypertension, exacerbates, it should be reported as an AE. This often requires the coordinator to investigate with the patient and consult the Principal Investigator (PI) to determine if it's due to non-compliance or a worsening of the condition. Thorough documentation is essential to explain any anomalies to auditors.

The Principal Investigator (PI) must assess every AE, determining its severity and relationship to the study drug. The PI is ultimately responsible for overseeing the progress of each adverse event. Coordinators also play a vital role in educating patients about what AEs are and how to report them, both during scheduled visits and for events that occur between visits. Patients should understand that even seemingly minor events can be significant in an experimental study and must be reported for their safety.